查詢結果分析
相關文獻
- 復發惡性腦膜瘤患者之補救性硼中子捕獲治療與照護系統
- 復發性兒童腦幹腫瘤患者之硼中子捕獲治療
- 臺灣粒子治療的現況與展望
- 利用精準性硼中子捕獲治療(BNCT)來補救治療復發性兒童腦瘤病人
- 放射治療後長期存活之鼻咽癌病人的生活品質調查
- 鼻咽癌病患放射治療後生活品質之研究
- 硼中子捕獲治療(BNCT)之治療計畫驗證與臨床應用
- Intraventricular Meningioma Occurring after the Transsphenoidal Removal of a Pituitary Adenoma Without Irradiation: A Case Report
- 第一期下期與第二期上期之子宮頸癌經不同治療模式後的長期生活品質比較
- 早晚期鼻咽癌病患經放射治療後與時間相關之生活品質分析
頁籤選單縮合
| 題 名 | 復發惡性腦膜瘤患者之補救性硼中子捕獲治療與照護系統=Treatment Outcomes and Care System for Salvage Boron Neutron Capture Therapy (BNCT) in Recurrent Malignant Meningioma Patients |
|---|---|
| 作 者 | 陳一瑋; 黃廷宇; 穆佩芬; 林俊甫; 李宜燕; 林可瀚; 賴律翰; 潘伯申; 田中浩基; 郭于誠; 李芃逸; 李家誠; 劉鴻鳴; 裴晉哲; 周鳳英; | 書刊名 | 秀傳醫學雜誌 |
| 卷 期 | 24:1 2025.04[民114.04] |
| 頁 次 | 頁80-90 |
| 分類號 | 415.938 |
| 關鍵詞 | 腦膜瘤; 硼中子捕獲治療; 放射治療; 生活品質; 全人照護; Meningioma; Boron neutron capture therapy; Radiotherapy; Quality of life; Holistic care; |
| 語 文 | 中文(Chinese) |
| DOI | 10.30185/SCMJ.202504_24(1).0009 |
| 中文摘要 | 腦膜瘤是常見的中樞神經系統腫瘤,其源自神經組織外圍的結締組織突變,依其腫瘤表現分類為良性、非典型及惡性三類。惡性腦膜瘤處置以手術及放射治療為主,藥物僅有輔助角色。然而經標準治療後仍不幸復發者,尚缺乏有效的補救性處置。臺北榮總暨清華大學硼中子捕獲治療團隊自2017年起透過恩慈療法模式,對傳統療法失效的復發惡性腦瘤患者,提供硼中子捕獲治療之緊急醫療協助。除此之外,團隊亦提供了高品質的腫瘤治療照護系統,來改善治療後的復原效率,並兼顧身心全面的完整照護。本篇報告探討一位復發之腦膜瘤個案,經硼中子捕獲治療後成效甚佳,至今超過一年以上追蹤無復發,且無嚴重治療後不適症狀發生。此優質的醫療處置模式值得全面性的推廣。 |
| 英文摘要 | Meningioma represents a commonly diagnosed central nervous system neoplasm in Taiwan. Etiologically, this type of tumor has been linked to mutations in the connective tissue adjacent to the brain. Based on the World Health Organization's classification system, meningiomas are categorized into three groups, reflecting their behavior: benign, atypical, and malignant. The primary therapeutic modalities for malignant meningioma encompass surgical resection and radiation therapy. Yet, advancements in pharmacological interventions remain scarce. In the clinical realm, recurrence following conventional surgery, radiotherapy, or adjunctive treatments is not an uncommon for patients with malignant meningioma. Due to the dearth of potent salvage therapies, tumor recurrence frequently results in mortality. In 2017, the boron neutron capture therapy (BNCT) neuro-oncology teams of Taipei Veterans General Hospital and Tsinghua University pioneered a unique therapy model for recurrent malignant brain tumors (including meningioma). Employing this novel targeted particle radiation therapy, patients who have failed conventional therapy can achieve effective tumor control. Furthermore, the comprehensive team not only provided high-quality medical interventions, but also afforded holistic care to patients both physically and mentally. In this report, the disease course of a female patient with recurrent malignant meningioma is depicted. She was offered BNCT, and neither cancer recurrence nor serious complications were presented after treatment with more than one year of follow-up. Such a commendable, high-caliber, and efficacious therapeutic modality certainly merits extensive investigation and endorsement. |
本系統中英文摘要資訊取自各篇刊載內容。